Candida antigen - Nielson Biosciences
Alternative Names: Candida albicans antigen - Nielson Biosciences; Candida albicans skin test antigen - Nielson Biosciences; CandinLatest Information Update: 09 Oct 2025
At a glance
- Originator Nielsen BioSciences
- Developer Janssen Research & Development; Nielsen BioSciences
- Class Antigens; Diagnostic agents; Skin disorder therapies; Yeasts
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypersensitivity
- Phase III Warts
Most Recent Events
- 27 Aug 2025 Nielsen BioSciences completes a phase-III clinical trials in Warts (In adolescents, In adults, In the elderly) in USA (Intradermal) (NCT05889845)
- 26 Feb 2025 Nielsen plans regulatory submissions for Warts (Intradermal) in USA
- 26 Feb 2025 Nielsen Biosciences completes enrolment in phase-III trial for Warts (In adolescents, In adults, In the elderly) in USA (NCT05889845)